44 results about "Hyperpigment" patented technology

The present invention relates to compositions useful in treating hyperpigmentation and the various signs of dermatological aging in human skin. The present invention also relates to cosmetic compositions and methods of using such compositions that improve the aesthetic appearance of skin. Further, the present invention relates to methods of applying the compositions to the skin to effect treatment and to improve the aesthetic appearance of skin, particularly, by providing anti-aging benefits to the skin. These and other objects of the present invention are achieved by a method and composition that comprises (a) a de-pigmenting agent or anti-aging agent in an amount effective to prevent, treat and / or ameliorate pigmentation or the various signs of aging at an area of skin to which it is applied, and (b) a cosmetically or pharmaceutically acceptable vehicle. Suitable de-pigmenting agents include 3,3'-thiodipropionic acid, thiazolidine-2-carboxylic acid, Kaempferol-7-glucoside, perilla oil, and clofibrate and clofibrate analogs and / or derivatives, as well as those set forth below. Suitable anti-aging agents include 3,3'-thiodipropionic acid and / or its derivatives.

The present application discloses a method of applying electromagnetic radiation, preferably laser radiation, most preferably at differing wavelengths, to reduce the severity of the symptoms of lipodermatosclerosis, for example. The method can reduce the severity of cutaneous and subcutaneous induration, hyperpigmentation, hyperhidrosis or other fluid weeping from the skin, erythematous, leathery appearance and texture, and associated pain and discomfort. The most preferred method involves non-invasively painting the affected area with an Aura-i laser (532 nm wavelength, generally penetrating the skin at a depth of 3-4 mm) through sapphire cooling disks and with a Lyra-i laser (1064 nm wavelength, generally penetrating the skin more deeply, such as at a depth of 6-7 mm) also through sapphire cooling disks. The method preferably involves at least three such painting applications separated by two to six, and preferably four, week intervals.

The present invention relates to novel, topically applied, cosmetic / dermatological compositions for the treatment of hyperpigmentation disorders and photodamaged human skin. The subject compositions combat hyperpigmented skin. In addition, the compounds described can be used in the treatment of many other pathologies. Due to a high degree of gentleness, along with potent antioxidant and moisturizing effects, the present invention can be used safely in the treatment of many conditions, such as the prevention and / or treatment of melasma, freckles, age spots (lentigo senilis) and photodamaged skin.

Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.

This invention relates to topical compositions comprising soy products and dioic acids and their use in skin lightening, against hyperpigmentation and, in particular, against skin spots.

The present invention relates to compounds, compositions, and methods for brightening skin. The compounds, compositions, and methods of the present invention generally involve compounds produced by a Malassezia yeast, and chemical analogs thereof. In addition to skin brightening applications, the compounds, compositions, and methods of the present invention may be used to modulate melanocyte activity, induce melanocyte apoptosis, agonize an arylhydrocarbon receptor (AhR), improve hyperpigmentation caused by a hyperpigmentation disorder, and modulate melanin production, melanosome biogenesis, and melanosome transfer.

Topically applicable skin depigmenting compositions, suited for treatment of such hyperpigmentary disorders as melasma and chloasma, contain a thus effective amount of at least one skin depigmenting active agent, for example hydroquinone or 4-hydroxyanisole, in admixture with a depigmentation-accelerating amount of adapalene (6-[3-(1-adamantyl)-4-methoxyphenyl]-2-napthanoic acid), and optionally with at least one sunscreen, formulated into a topically applicable, physiologically acceptable medium therefor.

A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.

The subject of the present invention is acrochordon removal and prevention utilizing safe dependable effective biocompatable treatments with no scarring, bleeding, twisting, yanking, choking, burning, freezing, shocking, screaming and hypo pigmentation or hyper pigmentation. In one aspect of the invention, methods are provided for acrochordon removal comprising application of high concentrations of hydrogen peroxide.

Methods and formulations are provided to reduce pigmentation in skin, using an array of compounds selected from benzimidazoles, phenylthioureas, phenyltiols, phenylamines, bi- and multicyclic phenols, thiopheneamines, and benzothiamides. The compounds preferably inhibit pigment systhesis in melanocytes through the tyrosinase pathway. The methods can be used for lightening skin, and for treating uneven skin complexions which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically.

The compositions and methods of described herein comprise novel ingredients effective to reduce unwanted pigmentation, such as skin discoloration, freckles, age spots, liver spots, sun damage, tans, pigmented acne marks, scars, pigmented birthmarks, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, melasma, cholasma, after-burn scar, nail stain, yellowing of skin, dark circles under eyes, and the like. The composition may include additional ingredients accordingly for a colored cosmetic, moisturizer, cleanser, toner, and the like.

The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and / or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.

A method of improving the appearance of a hyperpigmented spot and improving skin tone may comprise the steps of applying a safe and effective amount of a Laminaria Saccharina extract to a hyperpigmented spot on a skin surface, wherein the Laminaria Saccharina extract is applied for a period of time sufficient to improve the appearance of the hyperpigmented spot; and of applying a skin tone agent to the skin surface, wherein said tone agent is a vitamin B3 compound and wherein the tone agent is applied for a period of time sufficient to improve skin tone.

The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising:a) a safe and effective amount of a hexamidine compound selected from the group consisting of hexamidine, its salts, and derivatives;b) a safe and effective amount of one or more skin care active selected from the group consisting of sugar amine, vitamin B3, retinoid, peptide, phytosterol, butylated hydroxytoluene and butylated hydroxyanisole, their derivatives, and combinations thereof; andc) a dermatologically acceptable carrier for the hexamidine and the skin care active.In additional embodiments, the above composition is suitable for preventing, retarding, and / or treating dark under-eye circles, puffy eyes, sagging, sallowness as well as spider vessels and / or red blotchiness of skin, promoting skin desquamation, exfoliation, and / or turnover, regulating and / or reducing pore size appearance, preventing / retarding tanning, regulating oily / shiny appearance, preventing, retarding, and / or treating hyperpigmentation in mammalian skin, preventing, retarding, and / or treating itchiness of mammalian skin, preventing, retarding, and / or treating dryness of skin, preventing, retarding, and / or treating fine lines and wrinkles, preventing, retarding, and / or treating skin atrophy of mammalian skin, softening and / or smoothing lips, hair and nails of a mammal, and preventing, retarding, and / or treating the appearance of cellulite in mammalian skin.

The present invention provides a method of treating a subject afflicted with hyperpigmentation or of lightening the skin tone of a subject comprising administering to the subject an amount of a compound having the structure:or a salt or ester thereof, so as to thereby treat the subject or lighten the skin tone of the subject.

A method of identification of tricyclic compounds (formula I) that control melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to modify (e.g., inhibit) melanin production are disclosed.The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, hyperpigmentation and others.

This invention relates to a composition comprising a synergistic combination of ketoconazole and sulforaphane for use in skin lightening. This invention is based on the fact that a combination of ketoconazole and sulforaphane has been found to synergistically inhibit pigment production in B16 monolayer cultures. Thus the composition, when applied topically or imbibed over an appropriate length of time in-vivo, would be expected to cause skin lightening, or to reduce blemishes and / or hyperpigmented spots and / or solar lentigines leading to an improvement in skin tone and evenness.

A method is provided for identifying a material having an efficacy for reducing color contrast between a hyperpigmented skin lesion and skin surrounding the hyperpigmented skin lesion without directly affecting melanocytes or melanogenesis. The method includes the steps of applying a composition containing a material to be tested to the hyperpigmented skin lesion; and after an interval of time, observing whether the composition has effected at least one of inhibiting proliferation of keratinocytes, stimulating differentiation of keratinocytes, and improving compressive deformation of dermal papillae, in a basal layer of epidermis in the hyperpigmented lesion of skin.

A method for the identification of compounds) that control melanin synthesis (melanogenesis), and the preparation and use of such compounds, and compositions and formulations thereof to modify (e.g., inhibit) melanin production are disclosed. A representative compound of the invention is defined by formula I:The compounds may be prepared as pharmaceutical and cosmetic compositions, and in one embodiment, may be prepared in combination with each other, and with other melanogenesis inhibiting formulations. The compounds, compositions and formulations of the invention may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.

Provided is a composition. The composition comprises a compound having the structure of Formula (1). The composition reduces the synthesis of melanin by inhibiting the activity and expression levels of tyrosinase and related proteins, thereby preventing and limiting the content and distribution of melanin in mammalian skin. It also induces autophagy of melanosome, thereby restricting the synthesis, storage and transfer of melanin from melanocyte to keratinocyte. The dual modes of action allow for the efficacy of the composition at low dosage without causing toxicity to lighten skin and treat disorders associated with hyperpigmentation.

The present invention includes compounds, compositions comprising the same, and methods using the compounds and / or compositions therein, for modulating skin pigmentation in a mammalian subject. In certain embodiments, the compounds of the invention treat or prevent skin disorders or diseases associated with hyperpigmentation in the subject. In other embodiments, the compounds of the invention act as antagonist to the non-canonical sex steroid hormone receptor GPRE1 and do not bind to a canonical nuclear estrogen receptor (ER). In yet other embodiments, the compounds of the invention comprise acts as agonists to the non-canonical sex steroid hormone receptor PAQR7 and do not bind to a canonical nuclear progesterone receptor (PR).

A system and method of improving the condition of skin by reducing or eliminating wrinkles and hyperpigmentation is presented. The method delivers stem cells into the dermal layer of the skin to increase the number and density of fibroblasts in the dermal layer which in turn increases collagen, elastin and hyaluronic acid production to improve the appearance of the skin. The method includes constructing a scaffolding within microperforations in the skin and administering a therapeutically effective amount of stem cells to the skin which are supported on the scaffolding to remain in the microperforations for weeks thus allowing the dermal layer of skin to rebuild to a more youthful state.

A system for identifying hyperpigmented spots in skin. The system includes an image capture device for capturing an image of a subject and a computer for analyzing the image. The computer stores logic that, when executed by the processor, causes the computer to receive the image of the subject, receive a baseline image of the subject, identify a hyperpigmented spot in the image of the subject, and annotate the image of the subject to distinguish the hyperpigmented spot in the image. The logic may also cause the system to classify the hyperpigmented spot into a predetermined class, determine a product for treating the hyperpigmented spot according to the predetermined class, and provide information related to the product for use by the subject.

Methods and apparatus for treating melasma and / or related hyperpigmentation disorders of a patient are disclosed. The treatment includes delivering laser pulses onto a body of the patient, wherein the delivering laser pulses includes two or more of the following steps: i) delivering laser pulses p1 onto the body, wherein each pulse of the laser pulses p1 is configured to have a diameter of at least 100 μm and a duration of at most 1 μs; 2) delivering laser pulses p2 onto the body, wherein each pulse of the laser pulses p2 is configured to have a diameter of at least 100 μm and a duration of more than 1 μs; 3) delivering laser pulses p3 onto the body, wherein each pulse of the laser pulses p3 is configured to comprise a plurality of microbeams, each microbeam having a diameter below 1 mm.

Desired skin colour is a major unmet consumer need around the world and especially in Asia. Consumers particularly desire even skin colour, absence of age spots (solar lentigines), absence of hyperpigmentation and lighter overall skin tone. One solution is to use biological actives that reduce the activity of melanocyte cells in skin. These cells, present in the basal layer of the epidermis, make the dark coloured pigment melanin and export it, in small export vesicles called melanosomes, to the neighbouring keratinocytes. It is well described in the literature that compounds which reduce melanin synthesis when topically applied to the skin will reduce skin darkness over time and can generate a more even skin tone. Tyrosinase is a very popular target for the regulation of melanocyte pigment production. However effective inhibitors of tyrosinase are bedevilled by safety issues causing, for example, melanocyte cell death, permanent depigmentation, irritation and allergic reactions. Often effective inhibitors kill melanocytes (for example hydroquinone) or cause sensitisation reactions. There is therefore a great need for safe and effective inhibitors of skin pigment production that work through an alternative safe mechanism. The inventors have observed that selected compounds of the same generic structure: or a salt thereof; wherein R1, R2, R3, R4 and R5 may be independently selected from the group consisting of —H, -halide, and methyl, ethyl, propyl, iso-propyl, butyl, and t-butyl moieties, inhibit melanin production in Melanoderms™.

The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and / or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.

The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia- derived compounds, including malassezin and indirubin, and / or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.